Literature DB >> 25120708

Basaloid squamous cell carcinoma of the maxillary gingiva: A case report and review of the literature.

Shule Xie1, Marius Bredell2, Hongyu Yang1, Shiyue Shen1, Huijun Yang1.   

Abstract

Basaloid squamous cell carcinoma (BSCC) is a rare, but distinct histologic variant of squamous cell carcinoma in the head and neck region. It is considered to have a poor prognosis due to its aggressive behavior and tendency to metastasize. The usual sites of BSCC are the floor of the mouth, hypopharynx and base of the tongue, and according to the English-language literature its presentation in the gingiva is somewhat uncommon. In the current report, the unusual case of a 40-year-old male is presented; the patient exhibited a painless irregular mass in the maxillary gingiva, which infiltrated the maxillary sinus, as observed by computed tomography. Hematoxylin and eosin-stained sections revealed a diagnosis of BSCC with typical central necrosis in the cancer nests, which contained basaloid and squamous cells. Immunohistochemistry revealed that p63 was weakly positive, high molecular weight cytokeratin (CK) was focally positive, and S-100, CK7, CK14 and vimentin were negative. It must be noted that histopathology results may be incorrectly interpreted as adenoid cystic carcinoma, undifferentiated carcinoma and basal cell adenocarcinoma.

Entities:  

Keywords:  basaloid squamous cell carcinoma; gingival carcinoma; immunohistochemistry; squamous cell carcinoma

Year:  2014        PMID: 25120708      PMCID: PMC4114586          DOI: 10.3892/ol.2014.2318

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Basaloid squamous cell carcinoma (BSCC) is an uncommon variant of squamous cell carcinoma (SCC), which was first described by Wain et al (1) in 1986. BSCC generally present in the upper aerodigestive tract, particularly in the larynx, hypopharynx and the base of the tongue (2). Ide et al (3) reported 46 cases of BSCC in the oral mucosa, where only one case occurred in the gingival tissues. In addition, Hirai et al (4) described two cases of BSCC in the mandibular gingiva. In the current study, an additional case of BSCC in the maxillary gingiva is presented and the clinical features of BSCC are reviewed according to the current literature. Patient provided written informed consent.

Case report

In October 2009, a 40-year-old male visited the outpatient clinic of Peking University, Shenzhen Hospital (Shenzhen, China) presenting with a painless irregular mass of the right maxillary gingiva as well as nasal obstruction following the presentation of the initial symptoms two months previously. The patient’s medical history was unremarkable. The patient had a history of smoking for a period of 15 years (frequency, 10/day), however, denied excessive alcohol consumption. The intraoral examination revealed a gray, irregular mass (size, 3×2.5×2 cm) in the right maxillary posterior buccal gingiva, which elicited marginal pain on palpation. An extraoral clinical examination identified various palpable, mobile lymph nodes in the right submandibular region, measuring ~1×1×1 cm that were firm and non-tender on palpation. A computed tomography (CT) scan demonstrated a tumor, which involved the right maxillary sinus and infiltrated the central region of the hard palate (Fig. 1). The chest CT was negative for distant metastatic lesions. The lesion was clinically and radiologically classified as cT4 cNx cM0, according to the American Joint Committee on Cancer (AJCC) staging manual (5). The treatment comprised of an extended surgical excision of the tumor, which involved a partial maxillectomy with mandibulectomy and ipsilateral functional neck dissection at levels I-III, where four enlarged lymph nodes were removed at level Ib.
Figure 1

Computed tomography images of the basaloid squamous cell carcinoma. (A and B) The mass invaded the maxillary sinus and the central region of the hard palate.

To investigate the excised tissue, the tissues were fixed in 10% buffered formalin and processed via the usual methods for paraffin embedding. The paraffin sections were stained with hematoxylin and eosin. Immunohistochemical staining was performed using the BOND-MAX automated immunostainer (Vision BioSystems, Melbourne, Australia) to further define the diagnosis of the tumor. The antibodies that were used for immunohistochemistry are presented in Table I. The antigen retrieval method was heat-induced epitope retrieval in EDTA at an alkaline pH (pH 8.0). Adequate positive and negative tissue controls were used.
Table I

Primary antibodies adopted for immunohistochemical staining.

AntibodyCloneSourceDilutionResult
p634A4Santa Cruza1:75+
CK7OV-TL12/30Dakob1:50
CK14LL002Novocastrac1:50
CK-H34βE12Dakob1:50+
VimentinV9Dakob1:50
S-100AntiserumDakob1:4,000

Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA);

Dako (Carpinteria, CA, USA);

Novocastra Laboratories (Newcastle, UK).

CK, cytokeratin; CK-H, high molecular weight cytokeratin.

Microscopically, the tissues from the primary site demonstrated that there were two cellular populations; epithelial-like and basaloid tumor cells. The basaloid cells formed the primary invasive component of the cancer nests and were arranged in cords, trabeculae and lobules that occasionally demonstrated a pseudoglandular formation. These cells exhibited peripheral palisading and hyperchromatic nuclei with a high nucleus-cytoplasm ratio as well as a scant cytoplasm (Fig. 2A and B). Mitotic figures were observed within the nests and necrotic foci were scattered throughout the visual field. Components of SCC exhibiting keratinization were scarce, which differs to the features of conventional SCC. Immunohistochemically, the basaloid carcinoma cells were weakly positive for p63 (Fig. 2C) and focally positive for high molecular weight cytokeratin (CK-H; Fig. 2D), and negative for cytokeratin (CK)7, CK14, S-100 protein and vimentin. According to the clinical presentation, histopathological features and immunohistochemical findings, a final diagnosis of BSCC in the maxillary gingiva was determined. The surgical excision margins were healthy and the neck lymph node histopathology did not reveal any positive lymph nodes. The pathological staging of pT4 pN0 pM0 was established according to the AJCC staging manual.
Figure 2

(A) Histological sections of the basaloid squamous cell carcinoma (hematoxylin and eosin [H&E] stain; magnification, ×200) displayed central comedo-type necrosis in the cancer nest and (B) peripheral palisading with radially arranged cells at the periphery of the lobules. (C) Diffuse tumor cells were weakly positive for the p63 marker, and (D) intense high molecular weight cytokeratin-positivity was observed in the membrane and cytoplasm of the cancer cells (B–D: H&E stain; magnification, ×200).

However, the patient experienced recurrence half a year later and presented with a painful mass of the right cheek without enlarged lymph nodes on palpation. Following a failed tumor response to chemotherapy (dose, 16 mg pingyangmycin per day for seven days) and dimensional conformal radiotherapy (dose, 50 Gy), a second surgical intervention comprising of an extended resection of the neoplasm was conducted. Three years following treatment the patient remains free from tumor recurrence.

Discussion

BSCC is a rare and malignant tumor that presents in the head and neck region, including the oral mucosa, and has been defined as an aggressive and distinct variant of SCC, which is composed of basaloid and squamous components, according to the World health Organization (6). BSCC is particularly uncommon in the oral cavity and more so in the gingiva. According to Hirai et al (4), only eight cases of BSCC in the gingiva have been reported in the English literature (4,7–9), with only one case of BSCC occurring in the maxillary gingiva. The clinical features of the BSCC cases that presented in the gingiva are reviewed and summarized in Table II. Two patients were female and seven were male with an age range of 40–79 years (mean age, 60.1 years). The most frequent site of origin was the mandible (n=7) followed by the maxilla (n=2). According to the standard tumor-node-metastasis (TNM) staging, provided by the AJCC, three patients presented in stage I, two in stage II, three in stage III, and one in stage IV. All of the patients were treated using surgery, four underwent neck dissections and three received adjuvant radiotherapy. Five patients had survived at the median follow-up time of 56 months.
Table II

Reported cases of BSCC of the gingiva.

First author (ref)YearAge/genderStageLocation of lesionTreatmentFinal outcomeFollow-up period, months
Wedenberg et al (7)199755/MIMaxillaSA5
Abiko et al (8)199879/FIMandibleSA24
Yu et al (9)200861/MIIMandibleS + FNDA120
Yu et al (9)200856/MIVMandibleSD180
Yu et al (9)200865/MIIIMandibleSD2.5
Subramania et al (10)200972/FIIIMandibleS + FND + RTA12
Hirai et al (4)200955/MIIMandibleS + FNDA79
Hirai et al (4)200965/MIMandibleS + RTA60
Present case201040/MIIIMaxillaS + FND + RTA25

S, surgery; FND, functional neck dissection; RT, radiotherapy; A, alive; D, died.

The prognosis of patients with BSCC compared with patients with conventional SCC remains uncertain. Winzenburg et al (10) first identified that distant metastases occurred in 52% of patients with BSCC and in 13% of patients with poorly differentiated SCC. Soriano et al (11) showed that patients with SCC were associated with notably higher survival rates when compared with patients with BSCC; furthermore, the rate of distant metastasis was six times higher in the cases of BSCC. However, de Sampaio Góes et al (12) declared that the prognosis did not differ between patients with BSCC of the oral cavity and those with conventional SCC. The diagnosis of BSCC is currently based on histological criteria, including focal squamous differentiation, a basaloid pattern that is associated with frank invasive SCC or carcinoma in situ. However, the histopathological diagnosis of BSCC is difficult to differentiate from that of adenoid cystic carcinoma (ACC), poorly differentiated carcinoma and basal cell adenocarcinoma. BSCC may easily be misdiagnosed as ACC, particularly when a small biopsy sample is used. Previous studies have advocated that immunohistochemical markers, including CK7, CK14, p63, CK-H, S-100 and vimentin aid with distinguishing BSCC from ACC (13,14). Colleta et al (13) reported that the majority of cancer cells of ACC express CK7, which indicates a ductal-pattern possibly of salivary gland origin, while in BSCC, the basaloid cells exhibit positive expression for CK17 and negative expression for vimentin, S-100, CK7, CK8 or CK20. The p63 staining pattern of BSCC and ACC is markedly different; the positive p63 staining is diffused in ~100% of the BSCC cancer cells, while ACC demonstrates a compartmentalized pattern within the tumor nests (15). In addition, the expression of CK-H is positive in BSCC cases (14). In the present case the immunohistochemical staining was positive for p63 and CK-H, and negative for S-100, vimentin, CK14 and CK7. Thariat et al (16) also advocated another criterion (in addition to the original criteria and immunohistochemical findings reported by Wain et al [1]) and proposed that, owing to its dual behavior that is marginally dependent on its association with the human papilloma virus (HPV), the BSCC patients should be systematically examined for their HPV status as this may determine the treatment response (17). BSCC require aggressive multimodality treatment, including radical surgical excision, neck dissection, radiotherapy and regular chemotherapy due to the high overall mortality rate. Although chemotherapy is recommended by certain authors due to the high incidence of distant metastasis and the relatively poor prognosis (17), a standard chemotherapy regimen for BSCC has not yet been established. Furthermore, investigation of a greater number of patients is required to determine the efficacy of chemotherapy for BSCC of the head and neck. Bonner et al (18) advocated that immunotherapy elicited an improved treatment effect when compared with radiotherapy alone and resulted in a reduced mortality rate. In conclusion, the aggressive behavior of BSCC has been presented using a rare case of the maxillary gingiva. The potential difficulties of a histological diagnosis were discussed and the possible obstacles to an accurate diagnosis were emphasized. Further studies with uniform reporting are required in order to optimize the establishment of a diagnosis and define the optimum treatment strategies.
  17 in total

Review 1.  Prognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging system.

Authors:  Margaret Brandwein-Gensler; Richard V Smith
Journal:  Head Neck Pathol       Date:  2010-02-06

Review 2.  Basaloid squamous cell carcinoma of the head and neck: role of HPV and implication in treatment and prognosis.

Authors:  J Thariat; C Badoual; C Faure; C Butori; P Y Marcy; C A Righini
Journal:  J Clin Pathol       Date:  2010-10       Impact factor: 3.411

3.  Basaloid squamous cell carcinoma of the maxilla.

Authors:  C Wedenberg; P Jesslén; G Lundqvist; J Lundgren; H B Hellquist
Journal:  Oral Oncol       Date:  1997-03       Impact factor: 5.337

4.  p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma.

Authors:  Patrick Emanuel; Beverly Wang; Maoxin Wu; David E Burstein
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

5.  Basaloid squamous carcinoma of oral cavity: a histologic and immunohistochemical study.

Authors:  R D Coletta; P Cotrim; O P Almeida; V A F Alves; A Wakamatsu; P A Vargas
Journal:  Oral Oncol       Date:  2002-10       Impact factor: 5.337

6.  Basaloid-squamous cell carcinoma of the oral mucosa: report of two cases and study of the proliferative activity.

Authors:  Y Abiko; T Muramatsu; Y Tanaka; T Ohuchi; M Satoh; K Okumura; T Shibata; T Inoue; M Kanazawa; M Arisue; M Shimono; T Kaku
Journal:  Pathol Int       Date:  1998-06       Impact factor: 2.534

7.  Basaloid squamous cell carcinoma of the mandible: report of two cases.

Authors:  Eiji Hirai; Kozo Yamamoto; Noriaki Yamamoto; Yoshihiro Yamashita; Toshiaki Kounoe; Yoshihide Kondo; Hirotoshi Yonemasu; Tetsu Takahashi; Hideo Kurokawa
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-11

8.  Basaloid squamous carcinoma: a clinical comparison of two histologic types with poorly differentiated squamous cell carcinoma.

Authors:  S M Winzenburg; G A Niehans; E George; K Daly; G L Adams
Journal:  Otolaryngol Head Neck Surg       Date:  1998-11       Impact factor: 3.497

9.  The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition.

Authors:  K Shanmugaratnam; L H Sobin
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

10.  Basaloid squamous carcinoma of mandible.

Authors:  Balanand Subramanian; Karoon Agrawal; Kasinath Panda
Journal:  J Craniofac Surg       Date:  2009-01       Impact factor: 1.046

View more
  4 in total

1.  [Basaloid squamous cell carcinoma in gingiva: a case report].

Authors:  Lu-Ling Dai; Xiu-Xiu Yang; Hao-Wei Zhao; Qi Han; Yu Chen
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

2.  Basaloid Squamous Cell Carcinoma of the Head and Neck: Subclassification into Basal, Ductal, and Mixed Subtypes Based on Comparison of Clinico-pathologic Features and Expression of p53, Cyclin D1, Epidermal Growth Factor Receptor, p16, and Human Papillomavirus.

Authors:  Kyung-Ja Cho; Se Un Jeong; Sung Bae Kim; Sang-Wook Lee; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Pathol Transl Med       Date:  2017-06-08

3.  Basaloid squamous cell carcinoma: Report of two rare cases and review of literature.

Authors:  Kalavani Peddapelli; Guttikonda Venkateswara Rao; Taneeru Sravya; Sravya Ravipati
Journal:  J Oral Maxillofac Pathol       Date:  2018 May-Aug

4.  Cytokeratins (CK7 and CK20) Genes Expression Association with Clinicopathological Indices in Oral Squamous Cell Carcinoma and Dysplastic Oral Epithelium.

Authors:  Mehdi Shahabinejad; Reza Zare; Farnaz Mohajertehran; Atefeh Amouzad Mahdiraji
Journal:  Rep Biochem Mol Biol       Date:  2021-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.